Australian HTA Consults On Discount Rate
Key Economic Modelling Tool Under The Microscope
Executive Summary
PBAC, Australia’s health technology assessment body, is asking for feedback on whether its discount rate – a tool used in economic modelling – is too high.
You may also be interested in...
Australia Moves Closer To Reducing HTA Discount Rate For First Time In Decades
The pharmaceutical industry body Medicines Australia has welcomed an advisory committee’s recommendation on reducing the 5% discount rate that has been used in health technology assessments for 30 years, although it would have liked to see a bigger reduction and to have it implemented more quickly.
Missed Opportunities Punctuate NICE Reform, Says UK Industry
ABPI calls on UK to address lower investments in new medicines compared with comparable markets.
Australian Industry Signs Deal To Fund Access To Innovative New Drugs
Hot on the heels of Australia’s plan to overhaul the National Medicines Policy comes a new deal with the pharmaceutical industry to make new drugs available as soon as possible after approval and get patients more closely involved in reimbursement processes.